Related Experiment Video

Updated: Jun 17, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC

Karin Frank-Raue1, Susanne Rondot, Friedhelm Raue

  • 1Endocrine Practice, Molecular Laboratory, Brueckenstr. 21, Heidelberg 69120, Germany. karin.frankraue@raue-endokrinologie.de

Molecular and Cellular Endocrinology
|January 20, 2010
PubMed

Insights

Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome linked to RET gene mutations. Understanding these mutations guides early cancer detection and tailored treatments for better patient outcomes.

Area of Science:

  • Genetics
  • Oncology
  • Endocrinology

Background:

  • Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary cancer syndrome.
  • It is caused by specific missense gain-of-function mutations in the RET proto-oncogene.
  • MEN 2 encompasses three subtypes: MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC).

Purpose of the Study:

  • To highlight the strong genotype-phenotype correlations in MEN 2.
  • To emphasize the role of RET mutation analysis in guiding clinical management.
  • To underscore the importance of early diagnosis and prevention strategies for MEN 2.

Main Methods:

  • Review of existing literature on MEN 2.
  • Analysis of genotype-phenotype correlations.
  • Discussion of screening and diagnostic approaches.

Main Results:

  • Specific RET mutations correlate with distinct MEN 2 phenotypes and clinical courses.
  • Classification of RET mutations into risk levels informs surgical timing and extent.
  • Early diagnosis through calcitonin screening and RET-mutation analysis improves prognosis for medullary thyroid carcinoma (MTC).

Conclusions:

  • MEN 2 serves as a model for hereditary cancer prevention and cure.
  • Stratified, mutation-based diagnosis and therapy are crucial for managing MEN 2 carriers.
  • Early intervention based on genetic profiling offers an excellent prognosis for MTC.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...